Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accounts Payables: 2012-2025

Historic Accounts Payables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $1.9 million.

  • Enanta Pharmaceuticals' Accounts Payables fell 75.66% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 75.66%. This contributed to the annual value of $1.9 million for FY2025, which is 75.66% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Accounts Payables of $1.9 million as of FY2025, which was down 75.66% from $8.0 million recorded in FY2024.
  • Enanta Pharmaceuticals' 5-year Accounts Payables high stood at $9.5 million for FY2021, and its period low was $1.9 million during FY2025.
  • Over the past 3 years, Enanta Pharmaceuticals' median Accounts Payables value was $4.1 million (recorded in 2023), while the average stood at $4.7 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Accounts Payables soared by 95.31% in 2024 and then crashed by 75.66% in 2025.
  • Enanta Pharmaceuticals' Accounts Payables (Yearly) stood at $9.5 million in 2021, then plummeted by 37.11% to $6.0 million in 2022, then tumbled by 31.72% to $4.1 million in 2023, then surged by 95.31% to $8.0 million in 2024, then tumbled by 75.66% to $1.9 million in 2025.